For adults with rheumatoid arthritis (RA), there is a modest reduction in the mean Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) at three months for patients receiving tofacitinib (TOF) versus adalimumab (ADA), but there is no difference at nine months, according to a study published online June 29 in JAMA Network Open.
Leave A Comment